Recombinant Human HLA-A*02:01&B2M&KRAS WT(KLVVVGAGGV) Monomer Protein (HEK293)，Avi & His

HLA-A*02:01 is one of the most prevalent major histocompatibility complex (MHC) class I molecules in the human population, playing a critical role in the presentation of antigens to CD8+ T cells, which is essential for initiating immune responses against tumors and infections. The study of HLA-A*02:01 in conjunction with beta-2-microglobulin (B2M) is vital, as B2M is essential for the stability and surface expression of MHC class I molecules, thus influencing T cell recognition. The KRAS gene is frequently mutated in various cancers, leading to active RAS protein and consequent malignant transformation. In particular, the wild-type (WT) KRAS peptide KLVVVGAGGV has been identified as a potential target for T cell-based immunotherapy in KRAS-driven tumors. By investigating the recombinant monomer of HLA-A*02:01, B2M, and KRAS WT peptide, researchers aim to enhance our understanding of T cell receptor (TCR) interactions and the underlying mechanisms of immune recognition. This knowledge is crucial for the development of therapeutic strategies, including cancer vaccines and adoptive T cell therapies, to effectively target tumors expressing KRAS WT peptides, ultimately improving clinical outcomes for patients with solid tumors. Understanding the structural and functional dynamics of this complex can lead to innovative approaches in cancer immunotherapy, maximizing the efficacy of anti-tumor immune responses.